2:25 – 3:10pm Refreshment Break and Poster Viewing – Commonwealth Hall
2:30 – 2:45pm Speed Networking: Young Professionals
2:30 – 3:00pm Solutions Theater Presentation: Genetically Engineered MiniSwine as Translational Models of Preclinical Efficacy
Troy Arends, Director, Exemplar Genetics
3:10 – 4:10pm IO Plenary Session – Amphitheater
Join us for an IO focused Keynote Panel on Partnering Ecosystem as part of the IO Pharma Congress.
PANEL DISCUSSION: Partnering, Preclinical Strategies and Tools, IO Clinical Trials; Capital Invested in IO Relative to Other Oncology Areas
Leigh Zawel, PhD, CSO, Cullinan Oncology
Michael Woo, Director, Head of Immuno-Oncology Search & Evaluation, External Innovation, EMD Serono, Inc.
Sybil Williams, PhD, Director, Biology Oncology Discovery, Merck
Paul Young, PhD, Executive Director, Business Development & Licensing, Merck
Jernej Godec, PhD, Associate, Apple Tree Partners
Stacey J. Adam, PhD, Director, Cancer Research Partnerships, Foundation for the National Institutes of Health
- Has the IO bubble popped? Why have no other IO drugs emerged with PD1/PDL1-like efficacy?
- What combination strategies are being explored to convert poorly PD1 responsive tumors to more responsive ones?
- Are there new IO monotherapies or combos that appear promising?
- Is patient stratification practical with IO therapies?
- What partnering strategies are most effective?
- What is a recent deal your firm signed that you’re excited about?
4:20 – 5:20pm Plenary Keynote Presentation - Amphitheater
TURNING SCIENCE INTO MEDICINE: The Science behind the 5R Framework
Stephen Fawell, PhD, Vice President, Head Oncology Discovery, AstraZeneca
Improving R&D productivity is critical to the success of drug discovery, with failure rates from pre-clinical development to launch often in excess of 90 percent. In AstraZeneca, we conducted an in-depth review of our R&D activities to
help us identify ‘success factors’ that could improve the probability of success for any given drug discovery program. As a result, we launched the ‘5R framework’: right target, right tissue, right safety, right patient,
and right commercial, focused on the quality of our programs rather than the quantity of programs. In the five years since inception of this 5R framework our success rates have increased almost five-fold to 19% from pre-clinical investigation
to completion of Phase III clinical trials.
Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, Fidock M, Hamrén B, Johnson A, March RE, Matcham J, Mettetal J, Nicholls DJ, Platz S, Rees S, Snowden MA, Pangalos MN. Impact of a five-dimensional framework on R&D
productivity at AstraZeneca. Nature Reviews Drug Discovery (2018) 17, 167–181.
Cook D, Brown D; Alexander R, March R, Morgan P, Satterthwaite G and Pangalos MN. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nature Reviews Drug Discovery (2014) 13, 419-431.
MINING FOR TOMORROW’S CURES: A Nex-Gen Model of Drug Development
Jennifer Michaelson, PhD, Vice President, Preclinical Research & Early Development, Cullinan Oncology
Drug development in oncology and immuno-oncology is accelerating at a record pace. The multitude of drug targeting modalities and mechanisms being pursued within big pharma and biotech is astounding. Cullinan Oncology has a unique approach
to leverage the array of cutting-edge opportunities and broad range of scientific approaches within the fast moving oncology drug development space. A hybrid operating structure enables Cullinan to develop a diversified oncology portfolio
of single asset opportunities across a range of mechanisms and modalities within oncology and immune-oncology. The model entails a balance of externally and internally derived programs, a cost-efficient management structure, and an
outsourced model to drive speed, nimbleness, risk diversification and efficiency. Case studies exemplifying the efficiency in getting to key go/no go decisions will be presented. The ultimate goal is to develop high value oncology
therapeutics that have the potential to significantly improve upon standard of care for patients.
5:20 – 6:35pm Taste of New England Welcome Reception in the Exhibit Hall with Poster Viewing – Commonwealth Hall
5:25 Meet the Plenary Keynotes
6:20pm Amazon Echo Raffle!* – Commonwealth Hall
6:25 – 7:15pm Interactive Breakout Discussion Groups – Commonwealth Hall
7:30pm After Hours Networking at Seaport Hotel (Cash Bar Available)
Wednesday, June 19
Exhibit hall open from 9:35am – 6:05pm
9:35 – 10:20am Coffee Break and Poster Viewing – Commonwealth Hall
9:45 - 10:15am Solutions Theater Presentation: Automation Meets Cell Separation: Primary Cell Isolation for Drug Discovery Assays
Lotta Raety, Group Leader Cell Separation, Global Marketing, Miltenyi Biotec
Whether you are performing killing assays, immunophenotyping TILs, or investigating immunogenicity, primary cells are essential for the discovery of new therapeutics. Conclusive and relevant assay results depend on reliable sample preparation,
including cell separation and tumor dissociation. We have developed flexible automated solutions for primary cell isolation from various starting materials to ensure the best fit for every drug discovery program - join us to learn about the
best methods for your in vitro assays.
10:05am Poster Winner Announced
12:50 – 2:20pm Plenary Keynote Presentation - Amphitheater
Peter Henstock, PhD, AI & Machine Learning Lead, Pfizer
Litao Zhang, PhD, Vice President, Leads Discovery and Optimization, Bristol-Myers
Daniel Karlin, MD, Director of Biotech Ventures, CEAi, Inc
Peter Bergethon, Vice President, Quantitative Medicine & Clinical Technologies, Biogen
This panel will ask leaders focused on drug discovery and development how they view AI/ML/Digital as an opportunity over the next 1-5 years to improve their business including:
- In what parts of the business do they see the most opportunities and needs now?
- How does these technologies fit within their overall strategy?
- What is the right balance of partnering externally versus developing an internal Digital/AI team?
- What were the challenges in kickstarting the first AI/Digital projects?
2:20 – 3:05pm Booth Crawl and Dessert Break and Poster Viewing – Commonwealth Hall
2:25 Meet the Plenary Keynotes
2:55pm $300 Amazon Gift Card Raffle!* – Commonwealth Hall
5:10 – 6:05pm 4th of July Celebration (BBQ, Beer and Wine, Cornhole, Jenga, Fun!) and Poster Viewing – Commonwealth Hall
5:15 – 5:45pm Solutions Theater Presentation: The World's First Digital Lab Assistant
Guru Singh, Head, Growth, LabTwin
5:30 – 5:45pm Speed Networking: Oncology
5:55pm Bose® Soundlink® Raffle!* – Commonwealth Hall
6:15pm Evolving Regulatory Landscape in Digital Health – Meetup with Boston QSP - Harborview 2, Plaza Level (3rd Floor)
6:45pm After Hours Networking At Trillium Brewing Company: Fort Point Restaurant (Cash bar Available)
Thursday, June 20
Exhibit hall open from 10:15am – 2:20pm
7:15 – 8:10am Interactive Breakout Discussion Groups (with Continental Breakfast) – Commonwealth Hall
10:15 – 11:00am Coffee Break and Poster Viewing – Commonwealth Hall
10:15 – 10:45am Solutions Theater Presentation: Structural Maturation in the Development of hiPSC-Cardiomyocyte Models for Pre-clinical Safety, Efficacy, and Discovery
Nicholas Geisse, PhD, CSO, NanoSurface Biomedical
hiPSC-CM maturation is sensitive to structural cues from the extracellular matrix (ECM). Failure to reproduce these signals in vitro can hamper experimental reproducibility and fidelity. Engineering approaches that address this gap typically trade
off complexity with throughput, making them difficult to deploy in the modern drug development paradigm. The NanoSurface Car(ina)™ platform leverages ECM engineering approaches that are fully compatible with industry-standard instrumentation
including HCI- and MEA-based assays, thereby improving their predictive power.
10:45am Poster Winner Announced
10:50am $300 Amazon Gift Card Raffle!* – Commonwealth Hall
1:35 – 2:20pm Dessert and Coffee Break and Poster Viewing – Commonwealth Hall
1:45 – 2:00pm Speed Networking: Last Chance to Meet with Potential Partners and Collaborators!
2:15pm AncestryDNA™ Raffle!* – Commonwealth Hall
* Amazon, AncestryDNA™ and Bose® are not sponsors or participants of this event. Sponsors and exhibitors not eligible. Must be present to win!
**Exhibit hours are subject to change.*
Want to register for World Pharma Week? View the programs here